Ready to start your journey without the needle
Wang, Q., Wang, D., Cheng, A., Sun, F
We only succeed when employers and their employees do, too. To mark the announcement of these new products, which will be available in January, Noom also published a whitepaper today Breaking the GLP-1 Cost Cycle: Transforming Access, Cutting Costs, and Shaping the Future of Obesity Care
Higher doses up to 16 mg are under investigation in clinical trials outside China
Because this payment demonstration operates outside coverage under a Part D plan, the $50 copayment toward these medications will not count toward a participating beneficiarys Part D deductible or the $2,100 out-of-pocket maximum in 2026 (increasing to $2,400 in 2027), and copayments will stay consistent at $50 per month, regardless of the Part D benefit phase a beneficiary is in when they fill the prescription
These typically improve over time and can be minimized by following the dose escalation schedule